| [2] |
冯影，高明.94例甲状腺未分化癌临床分析[J].天津医科大学学报，2008，14（2）：207-209.
|
| [1] |
Haugen BR，Alexander EK，Bible KC，et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer：the AmericanThyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid，2016，26（1）：1-133.
|
| [3] |
Smallridge RC，Ain KB，Asa SL，et al.American thyroid association guidelines for management of patients with anaplastic thyroid cancer[J].Thyroid，2012，22（11）：1104-1139.
|
| [4] |
Bisof V，Rakusic Z，Despot M.Treatment of patients with anaplastic thyroid cancer during the last 20 years：whether any progress has been made?[J].Eur Arch Otorhinolaryngol，2015，272（7）：1553-1567.
|
| [5] |
Xu B，Ghossein R.Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma[J].Endocr Pathol，2016，27（3）：205-212.
|
| [6] |
Lennon P，Deady S，Healy ML，et al.Anaplastic thyroid carcinoma：failure of conventional therapy but hope of targeted therapy[J].Head Neck，2016，38（1）：E1122-E1129.
|
| [7] |
Santarpia L，El-Naggar AK，Cote GJ，et al.Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer[J].J Clin Endocrinol Metab，2008，93（1）：278-284.
|
| [8] |
Gupta N，Dasyam AK，Carty SE，et al.RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicularpattern cancers[J].J Clin Endocrinol Metab，2013，98（1），E914-E922.
|
| [9] |
Basolo F，Pisaturo F，Pollina LE，et al.N-ras mutation in poorly differentiated thyroid carcinomas：correlation with bone metastases and inverse correlation to thyroglobulin expression[J].Thyroid，2000，10（1）：19-23.
|
| [10] |
Howell GM，Hodak SP，Yip L.RAS mutations in thyroid cancer[J].Oncologist，2013，18（2）：926-932.
|
| [11] |
Rushton S，Burghel G，Wallace A，et al.Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma[J].Histopathology，2016，69（2）：524-526.
|
| [12] |
Riesco-Eizaguirre G，Rodríguez I，De la Vieja A，et al.The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer[J].Cancer Res，2009，69（21）：8317-8325.
|
| [13] |
Lim AM，Taylor GR，Fellowes A，et al.BRAF inhibition in BRAFV600E-positive anaplastic thyroid carcinoma[J].J Natl Compr Canc Netw，2016，14（3）：249-254.
|
| [14] |
Latteyer S，Tiedje V，Konig K，et al.Targeted next-generation sequencing for TP53，RAS，BRAF，ALK and NF1 mutations in anaplastic thyroid cancer[J].Endocrine，2016，54（3）：733-741.
|
| [15] |
Liu Z，Hou P，Ji M，et al.Hishly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways inanaplasticandfollicllarthyroidcancers[J].JClinEndocrinol Metab，2008，93（5）：3106-3116.
|
| [16] |
Zhang P，Wang C，Ma T，et al.O-GlcNAcylation enhances the invasion of thyroid anaplastic cancer cells partially by PI3K/Akt1 pathway[J].Onco Targets Ther，2015，8（1）：3305-3313.
|
| [18] |
SpitzwegC.Genetherapyinthyroidcancer[J].HormMetabRes，2009，41（6）：500-509.
|
| [22] |
Xing M.Molecular pathogenesis and mechanisms of thyroid.cancer[J].Nat Rev Cancer，2013，13（3）：184-199.
|
| [26] |
Miyamoto S.Nuclear initiated NF-κB signaling：NEMO and ATM take center stage[J].Cell Res，2011，21（3）：116-130.
|
| [17] |
Blagosklonny MV，Giannakakou P，Wojtowicz M，et al.Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells[J].J Clin Endocrinol Metab，1998，83（1）：2516-2522.
|
| [19] |
Soares P，Lima J，Preto A，et al.Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas[J]. Curt Genomies，2011，12（1）：609-617．
|
| [20] |
Mc Fadden DG，Vernon A，Santiago PM，et al.p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer[J].Proc Natl Acad Sci USA，2014，111（16）：E1600-E1609.
|
| [21] |
Garcia-Rostan G，Tallini G，Herrero A，et al.Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma[J].Cancer Res，1999，59（8）：1811-1815.
|
| [23] |
Kim HJ，Kim MJ，Kim A，et al.The role of notch 1 signaling in anaplastic thyroid carcinoma[J].Cancer Res Treat，2017，49（2）：509-517.
|
| [24] |
Ferretti E，Tosi E，Po A，et al.Notch signaling is involved inexpressionofthyrocytedifferentiationmarkersandisdownregulated in thyroid tumors[J].J Clin Endocrinol Metab，2008，93（10）：4080-4087.
|
| [25] |
Li J，Zheng X，Gao M，et al.Suberoyl bis-hydroxamic acid activates Notch 1 signaling and induces apoptosis in anaplas-tic thyroid carcinoma through p53[J].Oncol Rep，2017，37（3）：458-464.
|
| [27] |
Meng Z，Lou S，Tan J，et al.Nuclear factor-kappa B inhibition can enhance the rapeutic efficacy of131I on the in vivo management of differentiated thyroid cancer[J].Life Sci，2012，91（5）：1236-1241.
|
| [28] |
Yin Q，Liu S，Dong A，et al.Targeting transforming growth factor-beta1（TGF-beta1）inhibitstumorigenesisofanaplastic thyroid carcinoma cells through ERK1/2-NF kappa BPUMA signaling[J].Med Sci Monit，2016，22（1）：2267-2277.
|
| [29] |
Romei C，Elisei R.Ret/ptc translocations and clinico-pathological features in human papillary thyroid carcinoma[J]. Front Endocrinol（Lausanne），2012，（3）：54.
|
| [30] |
Kimura ET，Nikiforova MN，Zhu Z，et al.High prevalence of BRAF mutations in thyroid cancer：genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J].Cancer Res，2003，63（1）：1454-1457.
|
| [31] |
Greco A，Miranda C，Pierotti MA.Rearrangements of NTRK1 gene in papillary thyroid carcinoma[J].Mol Cell Endocrinol，2010，28，321（1）：44-49.
|
| [32] |
Antonelli A，Bocci G，Fallahi P，et al.CLM3，a multitarget tyrosine kinase inhibitor with antiangiogenic properties，is active against primary anaplastic thyroid cancer in vitro and in vivo[J].J Clin Endocrinol Metab，2014，99（1）：E572-E581.
|
| [33] |
Liu Z，Hou P，Ji M，et al.Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways inanaplasticandfollicularthyroidcancers[J].JClinEndocrinol Metab，2008，93（1）：3106-3116.
|
